NCT01647971 2022-11-21Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTG Therapeutics, Inc.Phase 1/2 Completed39 enrolled
NCT02006485 2019-11-05Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesTG Therapeutics, Inc.Phase 1 Completed160 enrolled